KZR · Kezar Life Sciences, Inc.
$7.29
+0.00 (+0.00%)
At close · May 11
Market Cap
$53.86M
Shares
7.39M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.29
Open$7.29
Day$7.29–7.29
52W$3.53–7.55
Avg vol 30d142K
Short int159K · 2.1% float · 2.3d
Short vol46%
Last earningsAug 5, 2020
DataJan 2020–May 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+26%
above
Price vs 50-day avg
+2%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
94%
near high
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+18%
trailing
YTD return
+16%
this year
Relative strength
+8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.15% of float · ▲ +4.6% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
44 holders — near 2-yr high, broad support
Fundamentals
EPS growth
+33%
Y/Y
Free cash flow
$-51.8M
Balance sheet
$71.9M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
1.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+26%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
94%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.15% of float · ▲ +4.6% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
44 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $7 · 94%
52-wk high $8
vs 200-day avg +26%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KZR
this stock
Kezar Life Sciences, Inc.
|
$53.86M | +15.9% | — | — | 2.1% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +8.2% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -9.8% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KZR | -1.4% | -1.9% | +18.0% | -0.3% | +15.9% |
| SPY | +2.5% | +7.8% | +10.0% | +2.9% | +8.4% |
| vs SPY | -3.9% | -9.6% | +7.9% | -3.2% | +7.5% |